Prices delayed by at least 15 minutes | Print


Ironwood Pharmaceuticals (IRWD)

Common Shares
Sell: $7.55|Buy: $8.13|Change: 0.01 (0.12%)

Open 

$8.16


Previous close 

$8.11


Trade high 

$8.18


Volume 

2,547,615


Year high 

$15.70


Year low 

$7.53


Dividend yield 

-


Market capitalisation 

$1.29 bn


P/E ratio 

10.31


ISIN 

US46333X1081


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 07/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Ironwood Pharmaceuticals+ 0.12
More...

Company profile

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.